Menlo Therapeutics Inc (MNLO)
VYNE Therapeutics (formerly Menlo Therapeutics) to Present at the Cantor Fitzgerald and H.C. Wainwright Investment Conferences in September
Menlo Therapeutics changes name to Vyne Therapeutics (NASDAQ:MNLO)
Menlo Therapeutics (MNLO) changed its name to Vyne Therapeutics and will trade under the symbol to 'VYNE'; effective trading today."We are excited to launch our new corporate identity as VYNE Therapeutics today, and are honored to be marking this important milestone in our company's history by ringing the Nasdaq closing bell," president & CEO David Domzalski commented.No change in outstanding common shares and stockholders rights.
Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics
Will commence trading under new Nasdaq Ticker "VYNE", September 8, 2020
Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics
Menlo Therapeutics Announces Corporate Name Change to VYNE Therapeutics
LifeSci Capital Sticks to Its Buy Rating for Menlo Therapeutics (MNLO)
Menlo Therapeutics Inc. (MNLO) Reports Q2 Loss, Tops Revenue Estimates
Menlo Therapeutics Inc. (MNLO) delivered earnings and revenue surprises of -476.19% and 472.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
FSLY, WDC among premarket losers
MicroVision (NASDAQ:MVIS) -30% on Q2 earnings.OraSure Technologies (NASDAQ:OSUR) -20% on Q2 earnings.Fastly (NYSE:FSLY) -18% on Q2 earnings.Blue Apron Holdings (NYSE:APRN) -18% on pricing equity offering.Inseego (NASDAQ:INSG) -15% on Q2 earnings.ADMA Biologics (NASDAQ:ADMA) -15% on Q2 earnings.Citius Pharmaceuticals (NASDAQ:CTXR) -15% after announcing "bought deal" offering.Sonos (NASDAQ:SONO) -13% on Q3 earnings.Houghton Mifflin Harcourt (NASDAQ:HMHC) -4% on Q2 earnings.Western Digital (NASDAQ:WDC) -12% on Q4 earnings.Wix.com (NASDAQ:WIX) -11% on Q2 earnings.Aileron Therapeutics (NASDAQ:ALRN) -11% on Q2 earnings.Caladrius Biosciences (NASDAQ:CLBS) -10% after CFO resigns.ADT (NYSE:ADT) -10% on Q2 earnings.MYOS RENS Technology (NASDAQ:MYOS) -9%.TherapeuticsMD (NASDAQ:TXMD) -9% on Q2 earnings.Professional Diversity Network (NASDAQ:IPDN) -9%.3D Systems (NYSE:DDD) -9% on Q2 earnings.Four Seasons Education (Cayman) (NYSE:FEDU) -8%.Infrastructure and Energy Alternatives (NASDAQ:IEA) -8%.MannKind (NASDAQ:MNKD) -8% on Q2 earnings.Transocean (NYSE:RIG) -8% after executing a private exchange agreement relating to the 0.5% Exchangeable Bonds due 2023.Proteostasis Therapeutics (NASDAQ:PTI) -7%.Menlo Therapeutics (NASDAQ:MNLO) -7% on Q2 earnings.Carnival (NYSE:CCL) -7% on launch of direct offering.WISeKey International Holding (NASDAQ:WKEY) -7%.Camping World Holdings (NYSE:CWH) -7% on Q2 earnings.
Menlo Therapeutics EPS misses by $0.93, beats on revenue (NASDAQ:MNLO)
Menlo Therapeutics (NASDAQ:MNLO): Q2 GAAP EPS of -$1.21 misses by $0.93.Revenue of $11.7M beats by $9.66M.Shares -1.9% PM.Press Release
Menlo Reports Second Quarter 2020 Financial Results and Provides Business Update
Conference Call Today at 8:30am Eastern Time
Analysts Offer Insights on Healthcare Companies: Menlo Therapeutics (NASDAQ: MNLO) and Inmune Bio (NASDAQ: INMB)
Menlo Therapeutics to Report Second Quarter 2020 Financial Results on August 6
Investors Grab MNLO Even Lower Than Its Secondary Stock Offering
Looking back to 6 days ago, Menlo Therapeutics Inc (MNLO) priced a 27,050,000 share secondary stock offering at $1.85 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time..
Menlo Therapeutics (MNLO) Received its Third Buy in a Row
After Cantor Fitzgerald and H.C. Wainwright gave Menlo Therapeutics (NASDAQ: MNLO) a Buy rating last month, the company received another Buy, this time
Menlo Therapeutics (MNLO) Received its Third Buy in a Row
After Cantor Fitzgerald and H.C. Wainwright gave Menlo Therapeutics (NASDAQ: MNLO) a Buy rating last month, the company received another Buy, this time from Northland Securities. Analyst Tim Chiang maintained a Buy rating on Menlo Therapeutics today and set a price target of $6.00. The company’s shares closed last Wednesday at $2.09. According to TipRanks.com,
Why Menlo Therapeutics Stock Sank Today
The pricing of the biotech's stock offering weighed on shares.
Healthcare - Top 5 Gainers / Losers
Gainers: Sientra (NASDAQ:SIEN) +25%. Tetraphase Pharmaceuticals (NASDAQ:TTPH) +20%. Immunic (NASDAQ:IMUX) +17%. China Jo-Jo Drugstores (NASDAQ:CJJD) +15%. Tenet Healthcare (NYSE:THC) +15%.Losers: Tita
Menlo Therapeutics drops 17% after pricing equity offering (NASDAQ:MNLO)
Menlo Therapeutics (NASDAQ:MNLO) has priced its public offering of ~27.1M common shares at $1.85/share, for expected gross proceeds of $50,042,500.Underwriters' over-allotment is an additional 4,057,
Menlo Therapeutics Announces Pricing of Offering of Common Stock
Menlo Therapeutics readies equity offering (NASDAQ:MNLO)
Menlo Therapeutics (NASDAQ:MNLO) initiates a public offering of common stock. Price, volume and terms have yet to be announced.Shares down 10% after hours.
Menlo Therapeutics Announces Proposed Offering of Common Stock
Menlo combo skin foam shows positive action in mid-stage acne study (NASDAQ:MNLO)
Menlo Therapeutics (MNLO -4.4%) announces positive, though mixed, results from a 447-subject Phase 2 clinical trial, Study FX2016-40, evaluating FCD105 (3% minocycline/0.3% adapalene foam) for the tre
Menlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105 for the Treatment of Moderate-to-Severe Acne Vulgaris
The Company plans to present trial data along with a proposed Phase 3 development program in an End of Phase 2 meeting with the FDA before the end of this year
Menlo Therapeutics (MNLO) Received its Third Buy in a Row
After H.C. Wainwright and Cantor Fitzgerald gave Menlo Therapeutics (NASDAQ: MNLO) a Buy rating last month, the company received another Buy, this time